

=> b reg

FILE 'REGISTRY' ENTERED AT 15:42:58 ON 19 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2006 HIGHEST RN 872085-61-5
DICTIONARY FILE UPDATES: 17 JAN 2006 HIGHEST RN 872085-61-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d ide can l5

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 202646-79-5 REGISTRY
ED Entered STN: 15 Mar 1998
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-
thiazolylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H15 N5 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:533

REFERENCE 2: 128:154090

=> b hcap

FILE 'HCAPLUS' ENTERED AT 15:43:15 ON 19 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2006 VOL 144 ISS 4

FILE LAST UPDATED: 18 Jan 2006 (20060118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr 16 tot

L6 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:824128 HCAPLUS

DN 134:533

ED Entered STN: 24 Nov 2000

TI Novel use of adenosine A1A2a receptor dual antagonists

IN Matsuoka, Nobuya; Moriguchi, Akira; Tada, Miho; Mihara, Takuma

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

IC ICM A61K-0045/00

ICS A61K-0031/4985; A61K-0031/437; A61P-0025/22; A61P-0025/24;




A61P-0025/16; C07D-0471/04; C07D-0487/04

CC 1-11 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2000069464	A1	20001123	2000WO-JP03015	20000511
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP--1177797	A1	20020206	2000EP-0925617	20000511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US2004152659	A1	20040805	2003US-0716865	20031120
PRAI	1999JP-0131108	A	19990512		
	2000WO-JP03015	W	20000511		

2001US-0926469		B1	20011108
CLASS			
PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
-----	-----	-----	
WO 2000069464	ICM	A61K-0045/00	
	ICS	A61K-0031/4985; A61K-0031/437; A61P-0025/22; A61P-0025/24; A61P-0025/16; C07D-0471/04; C07D-0487/04	
	IPCI	A61K0045-00 [ICM,7]; A61K0031-4985 [ICS,7]; A61K0031-437 [ICS,7]; A61P0025-22 [ICS,7]; A61P0025-24 [ICS,7]; A61P0025-16 [ICS,7]; C07D0471-04 [ICS,7]; C07D0487-04 [ICS,7]	
	ECLA	A61K031/00+A; A61K031/50D15; A61K031/52+A; A61K031/52+M; C07D471/04+231C+221C; A61K031/437; A61K031/4985; A61K031/50+M	
	EP---1177797	IPCI	A61K0045-00 [ICM,6]; A61K0031-4985 [ICS,6]; A61K0031-437 [ICS,6]; A61P0025-22 [ICS,6]; A61P0025-24 [ICS,6]; A61P0025-16 [ICS,6]; C07D0471-04 [ICS,6]; C07D0487-04 [ICS,6]
	ECLA	A61K031/00+A; A61K031/437; A61K031/4985; A61K031/50+M; A61K031/50D15; A61K031/52+A; A61K031/52+M; A61K031/522; C07D471/04+231C+221C	
US2004152659	IPCI	A61K0031-7076 [ICM,7]; A61K0031-52 [ICS,7]	
	NCL	514/046.000	
	ECLA	A61K031/00+A; A61K031/437; A61K031/4985; A61K031/50+M; A61K031/50D15; A61K031/52+A; A61K031/52+M; A61K031/522; C07D471/04+231C+221C	
OS	MARPAT 134:533		
GI			



AB Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonists or salts thereof. Markush's structures of pyrazolopyridine derivs. (I), pyrazolopyrazine derivs. (II), and xanthine derivs. (III) were given.

ST adenosine A receptor antagonist parkinsonism antianxiety antidepressant

IT Purinoceptor antagonists
(A1; novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

IT Purinoceptor antagonists
(A2; novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

IT Antidepressants
Anxiolytics
Cognition enhancers
Mental disorder
Parkinson's disease
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

IT 69-89-6D, Xanthine, derivs. 110-86-1D, Pyridine, pyrazolo- derivs.,
biological studies 290-37-9D, Pyrazine, pyrazolo- derivs.
202646-79-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) Fujisawa Pharmaceutical Co Ltd; EP----925299 A1 HCAPLUS
(2) Fujisawa Pharmaceutical Co Ltd; WO---9803507 A1 1998 HCAPLUS
(3) Kyowa Hakko Kogyo Co Ltd; JP--06211856 A HCAPLUS
(4) Kyowa Hakko Kogyo Co Ltd; US---5484920 A HCAPLUS
(5) Kyowa Hakko Kogyo Co Ltd; US---5587378 A HCAPLUS
(6) Kyowa Hakko Kogyo Co Ltd; EP---590919 A1 1993 HCAPLUS
(7) Mally, J; Pharmacol Ther 1996, V72(3), P243 HCAPLUS
(8) Mandhane, S; Eur J Pharmacol 1997, V328(2/3), P135 HCAPLUS
(9) Ohno, M; Neuroreport 1996, V7(18), P3013 HCAPLUS
(10) Suzuki, F; J Med Chem V36(17), P2508 HCAPLUS

IT 202646-79-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

RN 202646-79-5 HCAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:87731 HCAPLUS

DN 128:154090

ED Entered STN: 14 Feb 1998

TI Preparation of pyrazolopyridine compounds as adenosine antagonists

IN Akahane, Atsushi; Kuroda, Satoru; Itani, Hiromichi; Shimizu, Yasuyo

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D-0471/04
ICS C07D-0453/02; A61K-0031/50; C07D-0471/04; C07D-0231/00; C07D-0221/00

CC 28-15 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO---9803507	A1	19980129	1997WO-JP02493	19970717
W: AU, CA, CN, HU, IL, JP, KR, NO, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 CA---2260990 AA 19980129 1997CA-2260990 19970717
 AU---9734621 A1 19980210 1997AU-0034621 19970717
 AU---733034 B2 20010503
 EP---925299 A1 19990630 1997EP-0930832 19970717
 EP---925299 B1 20020925
 R: 'AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 CN---1230186 A 19990929 1997CN-0197819 19970717
 JP2000514821 T2 20001107 1998JP-0506791 19970717
 AT---224893 E 20021015 1997AT-0930832 19970717
 ES---2179352 T3 20030116 1997ES-0930832 19970717
 US---6124456 A 20000926 1999US-0147543 19990119
 PRAI 1996AU-0001110 A 19960718
 1997WO-JP02493 W 19970717

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9803507	ICM	C07D-0471/04
	ICS	C07D-0453/02; A61K-0031/50; C07D-0471/04; C07D-0231/00; C07D-0221/00
	IPCI	C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50 [ICS,6]; C07D0471-04 [ICS,6]; C07D0231-00 [ICS,6]; C07D0221-00 [ICS,6]
CA---2260990	ECLA	C07D471/04+231C+221C
	IPCI	C07D0471-04 [ICM,6]; C07D0519-00 [ICS,6]; A61K0031-50 [ICS,6]; A61K0031-505 [ICS,6]; A61K0031-535 [ICS,6]; A61K0031-54 [ICS,6]; A61K0031-55 [ICS,6]
AU---9734621	IPCI	C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50 [ICS,6]
EP---925299	IPCI	C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50 [ICS,6]; C07D0471-04 [ICI,6]; C07D0231-00 [ICI,6]; C07D0221-00 [ICI,6]
CN---1230186	IPCI	C07D0471-04 [ICM,6]; C07D0453-02 [ICS,6]; A61K0031-50 [ICS,6]
JP2000514821	IPCI	C07D0471-04 [ICM,7]; A61K0031-501 [ICS,7]; A61P0001-04 [ICS,7]; A61P0003-10 [ICS,7]; A61P0009-00 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-12 [ICS,7]; A61P0025-00 [ICS,7]; A61P0037-06 [ICS,7]; A61P0043-00 [ICS,7]
AT---224893	IPCI	C07D0471-04 [ICM,7]; C07D0453-02 [ICS,7]; A61K0031-50 [ICS,7]; C07D0471-04 [ICS,7]; C07D0231-00 [ICS,7]; C07D0221-00 [ICS,7]
ES---2179352	IPCI	C07D0471-04 [ICM,7]; C07D0453-02 [ICS,7]; A61K0031-50 [ICS,7]; C07D0471-04 [ICI,7]; C07D0231-00 [ICI,7]; C07D0221-00 [ICI,7]
US---6124456	IPCI	C07D0471-04; A61K0031-497
	NCL	514/252.040; 544/238.000
OS	MARPAT 128:154090	
GI		



AB The title compds. [I; R1 = aryl; R2 = lower alkyl (un)substituted with unsatd. 3 to 8-membered heteromonocyclic group, etc.] are prepared I are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (preparation given) was reacted with 4-chloro-1-methyl-piperidine.HCl in the presence of NaH to give I (R1 = Ph, R2 = Me), which was tested and showed adenosine antagonistic activity.

ST pyrazolopyridine prepn adenosine antagonist; depression dementia anxiety treatment pyrazolopyridine prepn; pain cerebrovascular disease treatment pyrazolopyridine prepn; heart failure treatment pyrazolopyridine prepn

IT Adenosine receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
 (Al; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Dissociation
 (Electro-mech.; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
 (angina pectoris; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
 (arrest; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
 (bradyarrhythmia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
 (cerebrovascular; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Intestine, disease
 (constipation; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Mental disorder
 (dementia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Mental disorder
 (depression; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
 Kidney, disease
 (failure; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Intestine, disease
 (ileus; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Heart, disease
 (infarction, myocardial; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
 (infarction; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease
 (ischemia, transient; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Intestine, disease
 (ischemia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Kidney, disease
 (nephritis; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Arteriosclerosis
 (obliterans; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Pancreas, disease
 (pancreatitis; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Alzheimer's disease
 Anemia (disease)

Anxiety
 Asthma
 Diabetes mellitus
 Edema
 Gout
 Hypertension
 Immunosuppression
 Kidney, disease
 Multiple organ failure
 Multiple organ failure
 Obesity
 Pain
 Parkinson's disease
 Shock (circulatory collapse)
 Thrombosis
 Ulcer

(preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Toxicity

(renal; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Respiration, animal

Respiration, animal

Therapy

Therapy

(resuscitation, post; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Brain, disease

(stroke; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Death

(sudden infant death syndrome; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Inflammation

(systemic inflammatory response syndrome; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT Vein

(thrombophlebitis; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 69-93-2, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(hyperuricemia; preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 202646-79-5P 202646-80-8P 202646-82-0P 202646-84-2P

202646-85-3P 202646-87-5P 202646-89-7P 202646-90-0P 202646-91-1P

202646-92-2P 202646-93-3P 202646-94-4P 202646-95-5P 202646-96-6P

202646-97-7P 202646-98-8P 202646-99-9P 202647-00-5P 202647-01-6P

202647-02-7P 202647-03-8P 202647-04-9P 202647-05-0P 202647-06-1P

202647-07-2P 202647-08-3P 202647-09-4P 202647-10-7P 202647-11-8P

202647-12-9P 202647-13-0P 202647-14-1P 202647-15-2P 202647-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 106-52-5, 1-Methyl-4-hydroxypiperidine 498-94-2, Isonipecotic acid

501-53-1, Benzyl chloroformate 867-13-0, Triethylphosphonoacetate

2032-35-1, Bromoacetaldehyde diethyl acetal 5382-16-1,

4-Hydroxypiperidine 5382-23-0, 4-Chloro-1-methylpiperidine hydrochloride

24424-99-5, Di-tert-butyl dicarbonate 41979-39-9, 4-Piperidone

hydrochloride 50893-53-3, 1-Chloroethyl chloroformate 79099-07-3,

1-tert-Butoxycarbonyl-4-piperidine 104706-47-0 141060-69-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolopyridine compds. as adenosine antagonists)

IT 533-15-3P 3518-83-0P 4045-22-1P 19099-93-5P 20691-89-8P

21156-84-3P 77211-75-7P 84358-13-4P 86518-68-5P 105409-83-4P

109384-19-2P 109431-87-0P 118811-03-3P 135716-08-4P 135716-09-5P

141430-49-1P 202647-16-3P 202647-17-4P 202647-18-5P 202647-19-6P

202647-20-9P 202647-21-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pyrazolopyridine compds. as adenosine antagonists)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Fujisawa Pharmaceutical Co Ltd; EP---0379979 A 1990 HCAPLUS

(2) Fujisawa Pharmaceutical Co Ltd; EP---0467248 A 1992 HCAPLUS

(3) Fujisawa Pharmaceutical Co Ltd; WO---9325205 A 1993 HCAPLUS

(4) Fujisawa Pharmaceutical Co Ltd; WO---9518128 A 1995 HCAPLUS

(5) Uehara, Y; AM J HYPERTENS 1995, V8(12, PT 1), P1189


IT 202646-79-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyridine compds. as adenosine antagonists)

RN 202646-79-5 HCAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



=> => b uspatall

FILE 'USPATFULL' ENTERED AT 15:48:49 ON 19 JAN 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:48:49 ON 19 JAN 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l8 tot

L8 ANSWER 1 OF 2 USPATFULL on STN

AN 2004:197353 USPATFULL

TI Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist

IN Matsuoka, Nobuya, Souraku-gun, JAPAN

Moriguchi, Akira, Ibaraki-shi, JAPAN

Tada, Miho, Amagasaki-shi, JAPAN

Mihara, Takuma, Ikoma-gun, JAPAN

PA Fujisawa Pharmaceutical Co. Ltd., Osaka-shi, JAPAN (non-U.S. corporation)

PI US2004152659 A1 20040805

AI 2003US-0716865 A1 20031120 (10)

RLI Continuation of Ser. No. 2001US-0926469, filed on 8 Nov 2001, ABANDONED
A 371 of International Ser. No. 2000WO-JP03015, filed on 11 May 2000,
UNKNOWN

PRAI 1999JP-0131108 19990512

DT Utility

FS APPLICATION

LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1534

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Preventives and/or remedies for Parkinson's disease and symptoms
associating therewith such as anxiety, depression and/or memory disorder

which contain as the active ingredient an adenosine A.sub.1A.sub.2a receptor dual antagonist or salts thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202646-79-5

(novel use of adenosine A1A2a receptor dual antagonists in psychiatry)

RN 202646-79-5 USPATFULL

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 2 USPATFULL on STN

AN 2000:128488 USPATFULL

TI Pyrazolopyridine compound and pharmaceutical use thereof

IN Akahane, Atsushi, Hyogo, Japan

Kuroda, Satoru, Takatsuki, Japan

Itani, Hiromichi, Hyogo, Japan

Shimizu, Yasuyo, Osaka, Japan

PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

PI US---6124456 20000926

WO---9803507 19980129

AI 1999US-0147543 19990119 (9)

1997WO-JP02493 19970717

19990119 PCT 371 date

19990119 PCT 102(e) date

PRAI 1996AU-0001110 19960718

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1690

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pyrazolopyridine compound of formula (I) wherein R.sup.1 is aryl, and R.sup.2 is lower alkyl substituted with unsaturated 3 to 8-membered heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) which may have one or more substituent(s); a group of formula (1) wherein R.sup.3 is hydrogen, lower alkyl, ar(lower)alkyl or acyl, R.sup.4 is hydrogen or hydroxy, A is lower alkylene, m is an integer of 0 or 1, and n is an integer of 1 or 2; a group of formula (2) wherein R.sup.5 and R.sup.6 are each lower alkyl; or quinuclidinyl, or a salt the The pyrazolopyridine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 202646-79-5P

(preparation of pyrazolopyridine compds. as adenosine antagonists)

RN 202646-79-5 USPATFULL

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:56:13 ON 19 JAN 2006)

FILE 'HCAPLUS' ENTERED AT 14:58:04 ON 19 JAN 2006

L1 2 US2004152659/PN OR (US2003-716865# OR JP2000-3015# OR US2001-92
SEL AN 1
L2 1 E1-2 AND L1

FILE 'REGISTRY' ENTERED AT 14:58:40 ON 19 JAN 2006

FILE 'HCAPLUS' ENTERED AT 14:58:40 ON 19 JAN 2006
L3 TRA L2 1- RN : 4 TERMS

FILE 'REGISTRY' ENTERED AT 14:58:40 ON 19 JAN 2006
L4 4 SEA L3

FILE 'HCAPLUS' ENTERED AT 14:58:51 ON 19 JAN 2006

FILE 'REGISTRY' ENTERED AT 14:59:18 ON 19 JAN 2006
SEL RN 1
L5 1 E3 AND L4

FILE 'HCAPLUS' ENTERED AT 15:39:35 ON 19 JAN 2006
L6 2 L5

FILE 'HCAOLD' ENTERED AT 15:41:11 ON 19 JAN 2006
L7 0 L6

FILE 'USPATFULL, USPAT2' ENTERED AT 15:41:48 ON 19 JAN 2006
L8 2 L5

=>